

# Dinesh Khanna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7857016/publications.pdf>

Version: 2024-02-01

435  
papers

37,063  
citations

7672

79  
h-index

4741

175  
g-index

446  
all docs

446  
docs citations

446  
times ranked

25934  
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 239-261.	2.9	20
2	Response to: "Riociguat in systemic sclerosis: a potential for disease modification"™ by Jain and Dhir. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e117-e117.	0.5	0
3	Expansion of Fcγ <sub>3</sub> Receptor <sup>+</sup> CD11c <sup>+</sup> Positive Macrophages, Ficolin 1 <sup>+</sup> Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 329-341.	2.9	38
4	Rehabilitation Interventions in Systemic Sclerosis: A Systematic Review and Future Directions. <i>Arthritis Care and Research</i> , 2022, 74, 59-69.	1.5	10
5	Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. <i>Arthritis and Rheumatology</i> , 2022, 74, 13-27.	2.9	71
6	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. <i>Rheumatology</i> , 2022, 61, 1600-1609.	0.9	53
7	The association between hand disease severity and fatigue in individuals with systemic sclerosis: a scoping review. <i>Disability and Rehabilitation</i> , 2022, 44, 5827-5833.	0.9	2
8	Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. <i>Arthritis and Rheumatology</i> , 2022, 74, 518-526.	2.9	21
9	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.0	25
10	Symptom experience of limited cutaneous systemic sclerosis from the Patients'™ perspective: A qualitative study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 1519-26.	1.6	12
11	Reliability, validity, and responsiveness to change of the Patient-Reported Outcomes Measurement Information System self-efficacy for managing chronic conditions measure in systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 110-116.	1.0	3
12	Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 163-174.	0.9	3
13	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Associated Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 674-684.	2.5	57
14	Cognitive difficulties in people with systemic sclerosis: a qualitative study. <i>Rheumatology</i> , 2022, 61, 3754-3765.	0.9	3
15	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. <i>Arthritis Research and Therapy</i> , 2022, 24, 19.	1.6	8
16	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 168-178.	1.0	9
17	Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. <i>Rheumatology</i> , 2022, 61, 4155-4162.	0.9	8
18	Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSICIS trial. <i>Rheumatology</i> , 2022, 61, 4397-4408.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis. <i>Frontiers in Immunology</i> , 2022, 13, 814533.	2.2	5
20	Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. <i>JCI Insight</i> , 2022, 7, .	2.3	11
21	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. <i>Rheumatology</i> , 2022, 61, 4035-4046.	0.9	6
22	<scp>Adiposeâ€Derived</scp> Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1399-1408.	2.9	9
23	Management of scleroderma gastrointestinal disease: Lights and shadows. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 85-97.	1.0	4
24	Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States. <i>ACR Open Rheumatology</i> , 2022, 4, 596-602.	0.9	2
25	The clinical relevance of Raynaudâ€™s phenomenon symptom characteristics in systemic sclerosis. <i>Clinical Rheumatology</i> , 2022, , .	1.0	2
26	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. <i>Rheumatology</i> , 2022, 62, 234-242.	0.9	13
27	Practical management of Raynaud's phenomenon â€“ a primer for practicing physicians. <i>Current Opinion in Rheumatology</i> , 2022, 34, 235-244.	2.0	2
28	Gut microbe-derived metabolite trimethylamine N-oxide activates PERK to drive fibrogenic mesenchymal differentiation. <i>IScience</i> , 2022, 25, 104669.	1.9	8
29	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosisâ€™associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2021, 48, 1295-1298.	1.0	12
30	Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma. <i>Arthritis and Rheumatology</i> , 2021, 73, 520-529.	2.9	21
31	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 66-76.	1.0	12
32	Fatigue predicts future reduced social participation, not reduced physical function or quality of life in people with systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 187-193.	1.0	12
33	Rituximab for the treatment of systemic sclerosis-interstitial lung disease. <i>Rheumatology</i> , 2021, 60, 489-491.	0.9	11
34	New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 641-650.	0.5	25
35	Development of a Musculoskeletal Ultrasound Protocol to Examine Upper Extremity Rehabilitation Outcomes in Systemic Sclerosis. <i>Journal of Diagnostic Medical Sonography</i> , 2021, 37, 13-23.	0.1	2
36	Predictive Significance of Serum Interferonâ€™Inducible Protein Score for Response to Treatment in Systemic Sclerosisâ€™Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1005-1013.	2.9	21

#	ARTICLE	IF	CITATIONS
37	Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II. <i>ACR Open Rheumatology</i> , 2021, 3, 8-16.	0.9	7
38	Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. <i>Clinical Rheumatology</i> , 2021, 40, 965-971.	1.0	7
39	Fatigue and Its Association With Social Participation, Functioning, and Quality of Life in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2021, 73, 415-422.	1.5	31
40	UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1422-1426.	1.0	4
41	How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. <i>Clinical Rheumatology</i> , 2021, 40, 1611-1616.	1.0	12
42	Clinical and psychosocioeconomic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR). <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab027.	0.3	3
43	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 96-106.	5.2	118
44	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
45	Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. <i>Genome Medicine</i> , 2021, 13, 35.	3.6	26
46	Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. <i>Arthritis and Rheumatology</i> , 2021, 73, 837-847.	2.9	26
47	Treatment for systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2021, 33, 240-248.	2.0	27
48	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 209-221.	2.5	88
49	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , 2021, 11, e044765.	0.8	6
50	Intensive and app-delivered occupational therapy to improve upper extremity function in early diffuse cutaneous systemic sclerosis: a pilot two-arm trial. <i>Rheumatology</i> , 2021, 60, 5002-5011.	0.9	13
51	Factors influencing patient decision-making concerning treatment escalation in Raynaud's phenomenon secondary to systemic sclerosis. <i>Arthritis Care and Research</i> , 2021, 73, 1845-1852.	1.5	9
52	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA Dermatology</i> , 2021, 157, 851-858.	2.0	12
53	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201594.	1.0	6
54	Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1301-1310.	2.9	104

#	ARTICLE	IF	CITATIONS
55	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 635-652.	1.9	28
56	Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1523-1532.	2.9	30
57	Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1453-1460.	0.5	32
58	Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis. <i>Lancet Rheumatology</i> , The, 2021, 3, e321-e323.	2.2	1
59	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 170.	1.6	30
60	Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 560-562.	5.2	6
61	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScUE trial. <i>BMJ Open</i> , 2021, 11, e048541.	0.8	7
62	Rituximab for the treatment of systemic sclerosis: urgent need for an international randomised controlled trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e463-e465.	2.2	4
63	Genome-wide Reduction in Chromatin Accessibility and Unique Transcription Factor Footprints in Endothelial Cells and Fibroblasts in Scleroderma Skin. <i>Arthritis and Rheumatology</i> , 2021, 73, 1501-1513.	2.9	10
64	Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 1731-1737.	2.9	20
65	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	1.6	3
66	Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. <i>Arthritis Care and Research</i> , 2021, , .	1.5	3
67	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. <i>Vaccine</i> , 2021, 39, 6111-6116.	1.7	39
68	A case of recalcitrant linear morphea responding to subcutaneous abatacept. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 194-198.	1.0	5
69	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 10.	1.6	18
70	Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 154-164.	1.0	8
71	Interpretation of PFTs and Decline in PFTs. In <i>Clinical Practice</i> , 2021, , 139-149.	0.1	0
72	Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 43-51.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 43-51.	0.4	8
74	Patient perception of disease burden in diffuse cutaneous systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 66-76.	1.0	7
75	Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2020, 72, 316-325.	2.9	14
76	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	2.9	163
77	Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?. <i>Rheumatology</i> , 2020, 59, 464-466.	0.9	14
78	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. <i>Clinical Rheumatology</i> , 2020, 39, 93-102.	1.0	8
79	Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 115-118.	0.5	18
80	Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU®) patient-reported outcome instrument. <i>Arthritis Research and Therapy</i> , 2020, 22, 3.	1.6	13
81	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 650-660.	2.5	105
82	Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 143-151.	1.0	3
83	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020, 72, 723-733.	1.5	25
84	Development and Pilot Testing of MyGoutCare. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 320-326.	0.5	3
85	Patient-reported outcome instruments in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 90-102.	1.0	14
86	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 379-386.	0.5	97
87	Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 455-466.	1.0	7
88	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	2.2	34
89	Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 167-171.	1.0	7
90	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35

#	ARTICLE	IF	CITATIONS
91	Rheumatoid Arthritisâ€‘Associated Interstitial Lung Disease: Current Update on Prevalence, Risk Factors, and Pharmacologic Treatment. Current Treatment Options in Rheumatology, 2020, 6, 337-353.	0.6	35
92	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, 2020, 79, 1600-1607.	0.5	69
93	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine, the, 2020, 8, 963-974.	5.2	348
94	Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis. Cell Reports Medicine, 2020, 1, 100140.	3.3	42
95	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patientâ€‘Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. ACR Open Rheumatology, 2020, 2, 362-370.	0.9	31
96	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis and Rheumatology, 2020, 72, 879-895.	2.9	302
97	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Annals of the Rheumatic Diseases, 2020, 79, 724-726.	0.5	51
98	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care and Research, 2020, 72, 744-760.	1.5	420
99	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 963-967.	1.6	3
100	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 891-896.	1.6	26
101	Treatment of systemic sclerosisâ€‘associated interstitial lung disease: Lessons from clinical trials. Journal of Scleroderma and Related Disorders, 2020, 5, 61-71.	1.0	43
102	Management of systemic sclerosis: the first five years. Current Opinion in Rheumatology, 2020, 32, 228-237.	2.0	38
103	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1049-1058.	2.9	27
104	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1892-1896.	2.9	36
105	Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology, 2020, 59, 2156-2158.	0.9	11
106	Management of systemic sclerosisâ€‘associated interstitial lung disease in the current era. International Journal of Rheumatic Diseases, 2020, 23, 137-139.	0.9	6
107	<i>HLA</i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 552-562.	3.3	52
108	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.5	71



#	ARTICLE	IF	CITATIONS
109	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 2451-2464.	3.9	106
110	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 61-71.	1.0	14
111	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , 2019, 58, 567-579.	0.9	51
112	An interim report of the Scleroderma Clinical Trials Consortium working groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 17-27.	1.0	13
113	Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2019, 71, 435-447.	1.5	33
114	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
115	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
116	Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. <i>European Respiratory Journal</i> , 2019, 54, 1900586.	3.1	41
117	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. <i>Arthritis Research and Therapy</i> , 2019, 21, 202.	1.6	21
118	Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>Arthritis Research and Therapy</i> , 2019, 21, 23.	1.6	33
119	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1242-1248.	0.5	39
120	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. <i>Arthritis and Rheumatology</i> , 2019, 71, 2059-2067.	2.9	55
121	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. <i>RMD Open</i> , 2019, 5, e000826.	1.8	35
122	Capillary Proliferation in Systemic Sclerosis-Related Pulmonary Fibrosis: Association with Pulmonary Hypertension. <i>ACR Open Rheumatology</i> , 2019, 1, 26-36.	0.9	5
123	Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma. <i>Arthritis and Rheumatology</i> , 2019, 71, 1350-1359.	2.9	16
124	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 85-103.	0.6	8
125	Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1036-1040.	0.9	14
126	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 648-656.	0.5	79



#	ARTICLE	IF	CITATIONS
127	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 92-100.	2.5	28
128	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4350-4369.	2.9	34
129	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. <i>Journal of Rheumatology</i> , 2019, 46, 1316-1325.	1.0	23
130	Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3695-3702.	3.3	77
131	Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1339-1349.	2.9	54
132	FRI0310...UNIVERSITY OF CALIFORNIA LOS ANGELES SCLERODERMA CLINICAL TRIALS CONSORTIUM GASTROINTESTINAL TRACT 2.0 REFLUX-SCALE ASSOCIATES WITH IMPAIRED ESOPHAGEAL SCINTIGRAPHY FINDINGS IN SYSTEMIC SCLEROSIS. , 2019, , .		0
133	Management of systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2019, 31, 241-249.	2.0	67
134	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	1.0	45
135	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 122-130.	0.5	141
136	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease " Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , 2019, 46, 78-84.	1.0	13
137	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 327-328.	2.9	0
138	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	2.9	41
139	Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. <i>Arthritis Research and Therapy</i> , 2019, 21, 8.	1.6	17
140	Response to: "Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series" by Narvez. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e124-e124.	0.5	7
141	Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1059-1067.	1.6	30
142	Diagnosis of pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801904.	3.1	333
143	Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. <i>Journal of Rheumatology</i> , 2019, 46, 176-183.	1.0	23
144	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 18-26.	0.9	37

#	ARTICLE	IF	CITATIONS
145	Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 686-693.	1.6	34
146	Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 49-56.	0.4	1
147	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018, 70, 1373-1384.	1.5	54
148	Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study. <i>Arthritis Care and Research</i> , 2018, 70, 1653-1660.	1.5	17
149	Screening High-Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists. <i>Arthritis and Rheumatology</i> , 2018, 70, 971-972.	2.9	38
150	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 813-817.	0.9	21
151	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , 2018, 378, 35-47.	13.9	417
152	Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. <i>Arthritis Care and Research</i> , 2018, 70, 439-444.	1.5	53
153	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 128-132.	0.5	20
154	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 152-157.	0.9	13
155	Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases. <i>Quality of Life Research</i> , 2018, 27, 755-764.	1.5	52
156	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.5	236
157	Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 644-652.	2.5	77
158	Correlation of the American College of Rheumatology provisional composite response index in systemic sclerosis with serum biomarkers of fibrogenesis in an observational cohort. <i>Rheumatology</i> , 2018, 57, .	0.9	0
159	Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1286-1295.	1.5	74
160	Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans. <i>American Journal of Gastroenterology</i> , 2018, 113, 1701-1710.	0.2	96
161	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.0	33
162	Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213022.	0.5	36

#	ARTICLE	IF	CITATIONS
163	Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). <i>Chest</i> , 2018, 154, 862-871.	0.4	72
164	Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 912-919.	2.9	44
165	Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. <i>Arthritis and Rheumatology</i> , 2018, 70, 1654-1660.	2.9	10
166	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1634-1643.	2.9	74
167	Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1362-1371.	0.5	122
168	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. <i>PLoS ONE</i> , 2018, 13, e0189498.	1.1	25
169	pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. <i>JCI Insight</i> , 2018, 3, .	2.3	38
170	Randomised, double-blind, placebo-controlled trial of IL1-trap, riloncept, in systemic sclerosis. A phase I/II biomarker trial. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 146-149.	0.4	13
171	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017, 20, 99-106.	1.9	3
172	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1186-1192.	1.1	36
173	Pharmacokinetic optimization of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1744-1749.	1.0	42
174	Systemic sclerosis. <i>Lancet</i> , The, 2017, 390, 1685-1699.	6.3	1,423
175	Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. <i>Journal of Rheumatology</i> , 2017, 44, 795-798.	1.0	0
176	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017, 56, 1302-1311.	0.9	51
177	Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. <i>Arthritis and Rheumatology</i> , 2017, 69, 1903-1913.	2.9	124
178	Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. <i>Arthritis and Rheumatology</i> , 2017, 69, 1451-1460.	2.9	109
179	Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. <i>Journal of Rheumatology</i> , 2017, 44, 791-794.	1.0	14
180	Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease. <i>Chest</i> , 2017, 151, 813-820.	0.4	54

#	ARTICLE	IF	CITATIONS
181	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
182	Points to consider when doing a trial primarily involving the heart. <i>Rheumatology</i> , 2017, 56, v12-v16.	0.9	6
183	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. <i>Rheumatology</i> , 2017, 56, v33-v37.	0.9	4
184	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v27-v32.	0.9	23
185	Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta. <i>Rheumatology</i> , 2017, 56, 1970-1981.	0.9	43
186	Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v4-v11.	0.9	6
187	Muscle involvement in systemic sclerosis: points to consider in clinical trials. <i>Rheumatology</i> , 2017, 56, v38-v44.	0.9	27
188	Points to consider in renal involvement in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v49-v52.	0.9	12
189	Assessment of skin involvement in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v53-v66.	0.9	41
190	Points to consider "Raynaud" phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v45-v48.	0.9	23
191	Points to consider for skin ulcers in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v67-v71.	0.9	59
192	Health care utilization in patients with gout: a prospective multicenter cohort study. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 233.	0.8	8
193	Racial differences in health-related quality of life and functional ability in patients with gout. <i>Rheumatology</i> , 2017, 56, 103-112.	0.9	14
194	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , 2017, 122, S14-S17.	1.3	29
195	Clinical and serological features of systemic sclerosis in a multicenter African American cohort. <i>Medicine (United States)</i> , 2017, 96, e8980.	0.4	78
196	Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v17-v22.	0.9	13
197	Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. <i>Rheumatology</i> , 2017, 56, v23-v26.	0.9	9
198	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.0	321

#	ARTICLE	IF	CITATIONS
199	Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, S29-S35.	1.0	10
200	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 42-49.	1.0	25
201	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.0	62
202	Response to "Screening for Pulmonary Hypertension in Scleroderma"™. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, e6-e6.	1.0	0
203	Measuring Disease Activity and Outcomes in Clinical Trials. , 2017, , 637-648.		0
204	Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 106-113.	0.4	7
205	Progress and Priorities in Systemic Sclerosis: The Next 10 Years " Report from the World Scleroderma Foundation. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 7-9.	1.0	3
206	A randomized controlled trial of acupuncture for the treatment of Raynaud's phenomenon: the difficulty of conducting a trial in Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 226-233.	1.0	3
207	Systemic sclerosis trial design moving forward. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 177-180.	1.0	42
208	Emerging strategies for treatment of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 186-193.	1.0	41
209	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. <i>Journal of Rheumatology</i> , 2016, 43, 1672-1679.	1.0	222
210	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	1.5	48
211	Management of connective tissue diseases associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , 2016, 28, 236-245.	2.0	85
212	Characterisation of an epigenetically altered CD4 <sup>+</sup> CD28 <sup>+</sup> Kir <sup>+</sup> T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry. <i>Lupus Science and Medicine</i> , 2016, 3, e000147.	1.1	19
213	Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. <i>Annals of the American Thoracic Society</i> , 2016, 13, 793-802.	1.5	64
214	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016, 387, 2630-2640.	6.3	505
215	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1975.	3.8	95
216	Impact of National Institutes of Health Gastrointestinal PROMIS Measures in Clinical Practice: Results of a Multicenter Controlled Trial. <i>American Journal of Gastroenterology</i> , 2016, 111, 1546-1556.	0.2	24

#	ARTICLE	IF	CITATIONS
217	Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors. <i>Arthritis and Rheumatology</i> , 2016, 68, 2975-2985.	2.9	62
218	Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 907-913.	1.5	24
219	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	5.2	754
220	Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?. <i>Journal of Rheumatology</i> , 2016, 43, 1832-1837.	1.0	3
221	Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 252-269.	0.6	53
222	Gastrointestinal manifestations of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 247-256.	1.0	106
223	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2016, 18, 305.	1.6	58
224	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 167-178.	1.5	13
225	Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1704-1713.	1.5	23
226	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	1.6	18
227	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 299-311.	2.9	110
228	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 374-381.	0.5	76
229	Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1367-1371.	0.5	35
230	A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. <i>Postgraduate Medicine</i> , 2016, 128, 34-40.	0.9	25
231	Performance of Gout Impact Scale in a longitudinal observational study of patients with gout. <i>Rheumatology</i> , 2016, 55, 982-990.	0.9	12
232	Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. <i>Rheumatology</i> , 2016, 55, 745-754.	0.9	24
233	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 439-445.	1.6	23
234	Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2015, 67, 3016-3026.	2.9	123



#	ARTICLE	IF	CITATIONS
235	Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care&nbsp;setting. <i>Patient Preference and Adherence</i> , 2015, 9, 971.	0.8	24
236	Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1612-1620.	0.5	148
237	Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 136.	0.4	7
238	Reliability, validity and responsiveness to change of the Saint Georgeâ€™s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 1369-1379.	0.9	21
239	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosisâ€™ associated interstitial lung disease trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 372.	1.6	87
240	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , 2015, 42, 2512-2512.	1.0	3
241	Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group. <i>Journal of Rheumatology</i> , 2015, 42, 2460-2464.	1.0	39
242	Management of Gastrointestinal Involvement in Scleroderma. Current Treatment Options in <i>Rheumatology</i> , 2015, 1, 82-105.	0.6	64
243	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. <i>Rheumatology</i> , 2015, 54, 144-151.	0.9	30
244	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) â€™ Report from OMERACT CTD-ILD Working Group. <i>Journal of Rheumatology</i> , 2015, 42, 2168-2171.	1.0	142
245	Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. <i>Journal of Rheumatology</i> , 2015, 42, 1624-1630.	1.0	17
246	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	1.6	60
247	Distinctions Between Diagnostic and Classification Criteria?. <i>Arthritis Care and Research</i> , 2015, 67, 891-897.	1.5	386
248	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.5	96
249	Systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 241-248.	2.0	32
250	Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 149-155.	0.5	14
251	Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1032-1033.	2.5	7
252	Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 3153-3162.	0.3	23



#	ARTICLE	IF	CITATIONS
253	Old medications and new targeted therapies in systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 1944-1953.	0.9	45
254	Clinical Outcome Measures in Raynaud's Phenomenon. , 2015, , 279-286.		2
255	Assessing disease activity and outcome in systemic sclerosis (scleroderma). , 2015, , 1159-1164.		0
256	What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis?. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S117-22.	0.4	7
257	Item Response Theory, Computerized Adaptive Testing, and PROMIS: Assessment of Physical Function. <i>Journal of Rheumatology</i> , 2014, 41, 153-158.	1.0	149
258	Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. <i>Rheumatology</i> , 2014, 53, 704-713.	0.9	41
259	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , 2014, 16, 493.	1.6	44
260	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Gastrointestinal Symptom Scales. <i>American Journal of Gastroenterology</i> , 2014, 109, 1804-1814.	0.2	190
261	Outcome Measures in Acute Gout: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2014, 41, 558-568.	1.0	28
262	Il Buono, Il Brutto, Il Cattivo. <i>Thorax</i> , 2014, 69, 871-872.	2.7	0
263	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014, 69, 436-444.	2.7	100
264	OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout. <i>Journal of Rheumatology</i> , 2014, 41, 569-573.	1.0	26
265	Idiopathic or connective tissue disease-associated interstitial lung disease: a case of HRCT mimicry. <i>Thorax</i> , 2014, 69, 205-206.	2.7	2
266	Survival and Predictors of Mortality in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. <i>Arthritis Care and Research</i> , 2014, 66, 489-495.	1.5	132
267	Taking Charge of Systemic Sclerosis: A Pilot Study to Assess the Effectiveness of an Internet Self-Management Program. <i>Arthritis Care and Research</i> , 2014, 66, 778-782.	1.5	37
268	Interstitial Lung Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. <i>Annals of the American Thoracic Society</i> , 2014, 11, S169-S177.	1.5	37
269	Construct Validity of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2014, 66, 1725-1730.	1.5	24
270	Achieving Serum Urate Goal: A Comparative Effectiveness Study between Allopurinol and Febuxostat. <i>Postgraduate Medicine</i> , 2014, 126, 65-75.	0.9	20

#	ARTICLE	IF	CITATIONS
271	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. <i>Journal of Rheumatology</i> , 2014, 41, 99-105.	1.0	73
272	Autologous Hematopoietic Stem Cell Therapy in Severe Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2485.	3.8	9
273	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 55-62.	1.6	69
274	Treatment of acute gout: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 31-38.	1.6	73
275	Examining radiographic outcomes over time. <i>Rheumatology International</i> , 2014, 34, 271-279.	1.5	4
276	Targeting the Myofibroblast Genetic Switch: Inhibitors of Myocardin-Related Transcription Factor/Serum Response Factor-Regulated Gene Transcription Prevent Fibrosis in a Murine Model of Skin Injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 480-486.	1.3	92
277	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2014, 33, 207-214.	1.0	48
278	Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 536-541.	1.6	19
279	Improved Transplant-Free Survival in Patients With Systemic Sclerosis-Associated Pulmonary Hypertension and Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1900-1908.	2.9	40
280	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1340-1349.	0.5	633
281	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014, 53, 1172-1177.	0.9	83
282	Cellular Mechanisms of Tissue Fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. <i>American Journal of Physiology - Cell Physiology</i> , 2014, 307, C2-C13.	2.1	71
283	Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. <i>Thorax</i> , 2014, 69, 123-129.	2.7	61
284	GERD Symptoms in the General Population: Prevalence and Severity Versus Care-Seeking Patients. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2488-2496.	1.1	45
285	ImmunoChIP Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	2.6	182
286	Development of an Online Library of Patient-Reported Outcome Measures in Gastroenterology: The GI-PRO Database. <i>American Journal of Gastroenterology</i> , 2014, 109, 234-248.	0.2	25
287	Connective Tissue Disease-Associated Interstitial Pneumonia and Idiopathic Interstitial Pneumonia: Similarity and Difference. <i>Seminars in Ultrasound, CT and MRI</i> , 2014, 35, 29-38.	0.7	31
288	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-Results from the International Scleroderma Renal Crisis Survey. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 666-672.	1.6	115

#	ARTICLE	IF	CITATIONS
289	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52
290	Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2014, 16, 411.	1.6	20
291	Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2014, 66, 1731-1739.	1.5	26
292	Gastrointestinal Involvement in Systemic Sclerosis. , 2014, , 77-87.		0
293	Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego, Shortness of Breath Questionnaire. <i>Arthritis Care and Research</i> , 2013, 65, 454-463.	1.5	18
294	Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts. <i>Journal of Rheumatology</i> , 2013, 40, 1706-1711.	1.0	23
295	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
296	Recommendations for Screening and Detection of Connective Tissue Disease-associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatism</i> , 2013, 65, 3194-3201.	6.7	175
297	Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 1809-1817.	0.9	101
298	Definitions and Diagnosis of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D42-D50.	1.2	1,467
299	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.5	1,705
300	Evaluation of Test Characteristics for Outcome Measures Used in Raynaud's Phenomenon Clinical Trials. <i>Arthritis Care and Research</i> , 2013, 65, 630-636.	1.5	32
301	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013, 3, e003563.	0.8	104
302	Long-term safety of pegloticase in chronic gout refractory to conventional treatment. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1469-1474.	0.5	83
303	Skin Gene Expression Correlates of Severity of Interstitial Lung Disease in Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2917-2927.	6.7	39
304	Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. <i>European Respiratory Review</i> , 2013, 22, 515-525.	3.0	30
305	A Delphi Exercise to Identify Characteristic Features of Gout - Opinions from Patients and Physicians, the First Stage in Developing New Classification Criteria. <i>Journal of Rheumatology</i> , 2013, 40, 498-505.	1.0	25
306	Measuring response in the gastrointestinal tract in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 700-706.	2.0	57

#	ARTICLE	IF	CITATIONS
307	Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial. <i>Journal of Rheumatology</i> , 2013, 40, 455-460.	1.0	67
308	Treatment of early diffuse systemic sclerosis skin disease. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 166-71.	0.4	30
309	Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 57-63.	0.4	13
310	Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2012, 39, 1450-1457.	1.0	59
311	Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial. <i>Journal of Rheumatology</i> , 2012, 39, 1326-1333.	1.0	71
312	Early detection and management of pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2012, 21, 306-312.	3.0	94
313	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1335-1342.	0.5	82
314	<i>IRF5</i> polymorphism predicts prognosis in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1197-1202.	0.5	72
315	Articular involvement in systemic sclerosis. <i>Rheumatology</i> , 2012, 51, 1347-1356.	0.9	76
316	Small and Large Intestinal Involvement. , 2012, , 485-499.		1
317	Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 117.	1.0	152
318	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1447-1461.	1.5	598
319	Treatment of Interstitial Lung Disease. , 2012, , 421-427.		1
320	Measuring Disease Activity and Outcomes in Clinical trials. , 2012, , 661-671.		1
321	Feasibility and Construct Validity of PROMIS and "Legacy" Instruments in an Academic Scleroderma Clinic. <i>Value in Health</i> , 2012, 15, 128-134.	0.1	70
322	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care and Research</i> , 2012, 64, 1431-1446.	1.5	1,268
323	An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy. <i>Rheumatology International</i> , 2012, 32, 2725-2729.	1.5	9
324	Health-Related Quality of Life and Outcome Measures in Gout. , 2012, , 217-225.		1

#	ARTICLE	IF	CITATIONS
325	Disease modification and other trials in systemic sclerosis have come a long way, but have to go further. <i>Arthritis Care and Research</i> , 2012, 64, n/a-n/a.	1.5	3
326	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 625-639.	1.5	1,413
327	Arthritis in Systemic Sclerosis: Systematic Review of the Literature and Suggestions for the Performance of Future Clinical Trials in Systemic Sclerosis Arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 801-814.	1.6	32
328	Work productivity in scleroderma: Analysis from the University of California, Los Angeles scleroderma quality of life study. <i>Arthritis Care and Research</i> , 2012, 64, 176-183.	1.5	27
329	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	1.5	49
330	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 358-367.	1.5	77
331	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S23-9.	0.4	28
332	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
333	Adverse Events during the Scleroderma Lung Study. <i>American Journal of Medicine</i> , 2011, 124, 459-467.	0.6	30
334	Patterns of radiographic outcomes in early, seropositive rheumatoid arthritis: A baseline analysis. <i>Contemporary Clinical Trials</i> , 2011, 32, 160-168.	0.8	4
335	Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial. <i>Journal of Rheumatology</i> , 2011, 38, 990-996.	1.0	39
336	Methods of Formal Consensus in Classification/Diagnostic Criteria and Guideline Development. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 95-105.	1.6	290
337	Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4+ T cells in the broncho-alveolar lavage of patients with systemic sclerosis. <i>Clinical Immunology</i> , 2011, 141, 293-303.	1.4	23
338	Health-related quality of life in adults reporting arthritis: analysis from the National Health Measurement Study. <i>Quality of Life Research</i> , 2011, 20, 1131-1140.	1.5	24
339	The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS). <i>Arthritis Care and Research</i> , 2011, 63, S486-90.	1.5	115
340	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
341	Atherosclerosis in systemic sclerosis: A systematic review and meta-analysis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2078-2090.	6.7	152
342	Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 2797-2808.	6.7	105

#	ARTICLE	IF	CITATIONS
343	Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group. <i>Arthritis and Rheumatism</i> , 2011, 63, 3078-3085.	6.7	107
344	A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 3540-3546.	6.7	125
345	Prevalence and correlates of sleep disturbance in systemic sclerosis—results from the UCLA scleroderma quality of life study. <i>Rheumatology</i> , 2011, 50, 1280-1287.	0.9	48
346	Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. <i>Rheumatology</i> , 2011, 50, 330-334.	0.9	70
347	Minimally important differences of the gout impact scale in a randomized controlled trial. <i>Rheumatology</i> , 2011, 50, 1331-1336.	0.9	31
348	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 996-1002.	0.5	60
349	Understanding Gastrointestinal Distress: A Framework for Clinical Practice. <i>American Journal of Gastroenterology</i> , 2011, 106, 380-385.	0.2	34
350	Minimally Important Differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. <i>Journal of Rheumatology</i> , 2011, 38, 1920-1924.	1.0	46
351	Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. <i>Rheumatology</i> , 2011, 50, 740-745.	0.9	79
352	Gender and ethnicity differences in patients with diffuse systemic sclerosis—analysis from three large randomized clinical trials. <i>Rheumatology</i> , 2011, 50, 335-342.	0.9	29
353	A 54-Year Old Woman with Pain and Stiffness of Hands and Tendon Friction Rubs. , 2011, , 267-271.		1
354	Assessing disease activity and outcome in scleroderma. , 2011, , 1367-1371.		3
355	Quality indicator set for systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S33-9.	0.4	8
356	Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S15-21.	0.4	8
357	Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S22-5.	0.4	46
358	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. <i>Current Rheumatology Reviews</i> , 2010, 6, 138-144.	0.4	28
359	Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations. <i>Current Rheumatology Reviews</i> , 2010, 6, 145-150.	0.4	4
360	Evidence-based management of rapidly progressing systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 387-400.	1.4	63



#	ARTICLE	IF	CITATIONS
361	Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. <i>Arthritis Care and Research</i> , 2010, 62, 1772-1778.	1.5	29
362	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
363	Exercise-induced pulmonary hypertension associated with systemic sclerosis: Four distinct entities. <i>Arthritis and Rheumatism</i> , 2010, 62, 3741-3750.	6.7	74
364	Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 1244-1247.	0.9	25
365	Gout disease-specific quality of life and the association with gout characteristics. <i>Patient Related Outcome Measures</i> , 2010, 2010, 1.	0.7	50
366	The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 588-591.	0.5	52
367	Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study. <i>Clinical Trials</i> , 2010, 7, 85-89.	0.7	0
368	Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. <i>Rheumatology</i> , 2010, 49, 955-959.	0.9	47
369	Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 550-557.	1.0	12
370	An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes—Methodology and Preliminary Results. <i>International Journal of Rheumatology</i> , 2010, 2010, 1-7.	0.9	9
371	Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. <i>Rheumatology</i> , 2010, 49, 1184-1188.	0.9	49
372	Dr. Malaviya, et al reply. <i>Journal of Rheumatology</i> , 2010, 37, 673-673.	1.0	0
373	Dr. Malaviya, et al reply. <i>Journal of Rheumatology</i> , 2010, 37, 1543.1-1543.	1.0	0
374	Valuation of scleroderma and psoriatic arthritis health states by the general public. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 112.	1.0	7
375	Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy. <i>Ophthalmology</i> , 2010, 117, 133-139.e2.	2.5	159
376	Diagnosis and management of systemic sclerosis. <i>Indian Journal of Rheumatology</i> , 2010, 5, 69-75.	0.2	1
377	Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S42-6.	0.4	23
378	Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S55-62.	0.4	32



#	ARTICLE	IF	CITATIONS
379	Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009, 36, 2356-2361.	1.0	43
380	Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo. <i>Chest</i> , 2009, 136, 1333-1340.	0.4	127
381	Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. <i>Rheumatology</i> , 2009, 48, 1143-1146.	0.9	42
382	Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. <i>Rheumatology</i> , 2009, 48, 1537-1540.	0.9	46
383	A Randomized Study of Scleroderma Health State Values: A Picture Is Worth a Thousand Words, and Quite a Few Utilities. <i>Medical Decision Making</i> , 2009, 29, 7-14.	1.2	2
384	Validating and Assessing the Sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in Patients with Early Aggressive Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 1150-1157.	1.0	10
385	Preventing Tuberculosis Flare in Patients with Inflammatory Rheumatic Diseases Receiving Tumor Necrosis Factor- $\alpha$ Inhibitors in India -- An Audit Report. <i>Journal of Rheumatology</i> , 2009, 36, 1414-1420.	1.0	38
386	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009, 60, 1102-1111.	6.7	137
387	Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double-blind, randomized controlled trials. <i>Arthritis and Rheumatism</i> , 2009, 60, 2490-2498.	6.7	105
388	Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument. <i>Arthritis and Rheumatism</i> , 2009, 61, 1257-1263.	6.7	186
389	Rapamycin versus methotrexate in early diffuse systemic sclerosis: Results from a randomized, single-blind pilot study. <i>Arthritis and Rheumatism</i> , 2009, 60, 3821-3830.	6.7	86
390	Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. <i>Current Rheumatology Reports</i> , 2009, 11, 111-119.	2.1	45
391	Systemic Sclerosis (Scleroderma) and Raynaud's Phenomenon. , 2009, , 77-95.		0
392	Development of Criteria for Evaluating Clinical Response in Thyroid Eye Disease Using a Modified Delphi Technique. <i>JAMA Ophthalmology</i> , 2009, 127, 1155.	2.6	30
393	The disutility of chronic gout. <i>Quality of Life Research</i> , 2008, 17, 815-822.	1.5	37
394	A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: Coronary artery calcification in cases and controls. <i>Arthritis and Rheumatism</i> , 2008, 59, 591-597.	6.7	70
395	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , 2008, 59, 699-705.	6.7	109
396	Chapter 5 Gastrointestinal Involvement in Systemic Sclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 8, 51-61.	0.1	6

#	ARTICLE	IF	CITATIONS
397	Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis. <i>Medical Decision Making</i> , 2008, 28, 926-937.	1.2	27
398	Willingness to Pay for a Cure in Patients with Chronic Gout. <i>Medical Decision Making</i> , 2008, 28, 606-613.	1.2	17
399	Perceptions of disease and health-related quality of life among patients with gout. <i>Rheumatology</i> , 2008, 48, 582-586.	0.9	100
400	Evaluation of an Instrument Assessing Influence of Gout on Health-Related Quality of Life. <i>Journal of Rheumatology</i> , 2008, 35, 2406-2414.	1.0	71
401	The Minimally Important Difference for the Fatigue Visual Analog Scale in Patients with Rheumatoid Arthritis Followed in an Academic Clinical Practice. <i>Journal of Rheumatology</i> , 2008, 35, 2339-2343.	1.0	85
402	Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. <i>Journal of Rheumatology</i> , 2008, 35, 1966-71.	1.0	8
403	Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial. <i>Journal of Rheumatology</i> , 2008, 35, 466-8.	1.0	10
404	Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1026-1034.	2.5	411
405	Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1633-1640.	0.5	30
406	Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences. <i>Statistical Methods in Medical Research</i> , 2007, 16, 13-29.	0.7	11
407	Natural products as a gold mine for arthritis treatment. <i>Current Opinion in Pharmacology</i> , 2007, 7, 344-351.	1.7	326
408	Recombinant human anti- $\alpha$ transforming growth factor $\beta$ 1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007, 56, 323-333.	6.7	415
409	Health values of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 57, 86-93.	6.7	51
410	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , 2007, 56, 1676-1684.	6.7	93
411	Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. <i>Arthritis and Rheumatism</i> , 2007, 57, 440-447.	6.7	58
412	Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. <i>Arthritis and Rheumatism</i> , 2007, 57, 1280-1286.	6.7	63
413	Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. <i>Quality of Life Research</i> , 2007, 16, 1083-1092.	1.5	57
414	Outcome measures in systemic sclerosis: An update on instruments and current research. <i>Current Rheumatology Reports</i> , 2007, 9, 151-157.	2.1	57

#	ARTICLE	IF	CITATIONS
415	Systemic sclerosis - continuing progress in developing clinical measures of response. Journal of Rheumatology, 2007, 34, 1194-200.	1.0	64
416	Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. Journal of Rheumatology, 2007, 34, 1459-64.	1.0	72
417	Outcome evaluations in gout. Journal of Rheumatology, 2007, 34, 1381-5.	1.0	28
418	Health-related quality of life--an introduction. American Journal of Managed Care, 2007, 13 Suppl 9, S218-23.	0.8	63
419	Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Quality of Life Research, 2006, 15, 1383-1394.	1.5	27
420	Measuring Process of Arthritis Care: The Arthritis Foundation's Quality Indicator Set for Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism, 2006, 35, 211-237.	1.6	38
421	Association of tumor necrosis factor $\hat{\pm}$ polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis and Rheumatism, 2006, 54, 1105-1116.	6.7	49
422	COX-2 controversy: where are we and where do we go from here?. Inflammopharmacology, 2005, 13, 395-402.	1.9	15
423	Ayurvedic medicine: It is ?time? for scientifically sound studies. Seminars in Arthritis and Rheumatism, 2005, 34, 703-704.	1.6	4
424	Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung study. Arthritis and Rheumatism, 2005, 52, 592-600.	6.7	120
425	Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. Arthritis and Rheumatism, 2005, 52, 2284-2292.	6.7	39
426	Validation of single-factor structure and scoring protocol for the health assessment questionnaire-disability index. Arthritis and Rheumatism, 2005, 53, 536-542.	6.7	44
427	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. Journal of Rheumatology, 2005, 32, 832-40.	1.0	107
428	Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. Journal of Rheumatology, 2005, 32, 1040-2.	1.0	22
429	Scleroderma--developing measures of response. Journal of Rheumatology, 2005, 32, 2477-80.	1.0	15
430	Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort. Arthritis and Rheumatism, 2004, 50, 3093-3103.	6.7	42
431	Safety of Tumour Necrosis Factor-?? Antagonists. Drug Safety, 2004, 27, 307-324.	1.4	183
432	Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. Journal of Rheumatology, 2004, 31, 1686-92.	1.0	26

#	ARTICLE	IF	CITATIONS
433	Gouty tophi in a pancreatic pseudocyst. <i>Arthritis and Rheumatism</i> , 2002, 46, 565-566.	6.7	7
434	Angiocentric T cell lymphoma of the central nervous system in a patient with Sjögren's syndrome. <i>Journal of Rheumatology</i> , 2002, 29, 1548-50.	1.0	5
435	A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. <i>Rheumatology</i> , 0, , .	0.9	5